Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 2 CONFIDENTIAL  INVESTIGATOR’S AGREE MENT  
CONFIDENTIALITY  
The information in this protocol is provided to you, as an Investigator or consultant, for review by 
you, your staff, and an applicable institutional rev iew committee.  By accepting this document, 
you agree that information contained herein will be considered confidential and will not be 
disclosed to others, without written authority from The Romark Institute for Medical Research, 
except to the extent nece ssary to obtain: (a) Institutional Review Board approval and (b) informed 
consent from those persons to whom the investigational medicinal product will be administered.  
APPROVAL OF FINAL PROTOCOL  
My signature below constitutes agreement with this protocol.   I am providing the necessary 
assurances that this study will be conducted by me and my staff according to all stipulations of the 
protocol, including all statements regarding confidentiality, and in complete accordance with all 
applicable regulations inc luding current Good Clinical Practice guidelines and the ethical 
guidelines set by the World Medical Assembly ( Declaration of Helsinki , last amendment in 
Fortaleza, Brazil October 2013 ).  Furthermore, my signature below indicates that source 
documents will  be available for review by the Sponsor or their designated representative.  
 
Principal Investigator Signature:  
 
 
                         
Principal Investigator               Date  
  
Print name:           
 
With the signature below, the Sponsor approves of th is protocol.   
 
Sponsor Signature:  
 
 
                         
The Romark Institute for Medical Research         Date  
 
Print name:           
  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 3 CONFIDENTIAL  TABLE OF CONTENTS  
STATEMENT OF COMPLIA NCE  ................................ ................................ ................................ .1 
INVESTIGATOR’S AGREE MENT  ................................ ................................ ............................... 2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 3 
1. PROTOCOL SUMMARY  ................................ ................................ ............................ 6 
1.1. Synopsis  ................................ ................................ ................................ ........................ 6 
1.2. Schedule of Assessments  ................................ ................................ ............................ 10 
2. INTRODUCTION  ................................ ................................ ................................ ......11 
2.1. Coronavirus Disease 2019 (COVID -19) ................................ ................................ ....11 
2.2. Nitazoxanide (NTZ)  ................................ ................................ ................................ ....11 
2.2.1.  NTZ Inhibits Viral Replication and Cytokine Secretion  ................................ ............ 11 
2.2.2.  Pharmacokinetics of NTZ in Humans  ................................ ................................ ........ 13 
2.2.3.  Overview of Clinical Experience with NTZ  ................................ ............................... 14 
2.2.4.  Clinical Experience with NTZ in Treatment of Coronaviruses  ................................ ..14 
2.3. Rationale for the Study  ................................ ................................ ............................... 15 
3. STUDY OBJECTIVES  ................................ ................................ .............................. 15 
4. STUDY DESIGN  ................................ ................................ ................................ .......16 
4.1. Study Design Overview  ................................ ................................ .............................. 16 
4.2. Rationale for Important Issues in the Study Design  ................................ ................... 17 
4.2.1.  Choice of NTZ Dose and Duration of Treatment  ................................ ....................... 17 
4.2.2.  Choice of Duration of Follow Up  ................................ ................................ ............... 17 
4.2.3.  Choice of Control Group  ................................ ................................ ............................ 17 
4.2.4.  Choice of Patient Population  ................................ ................................ ...................... 17 
4.2.5.  Use of Vitamin B Complex Supplement  ................................ ................................ ....19 
4.2.6.  Choice of Patient -Reported Outcome Instrument  ................................ ....................... 19 
4.2.7.  Choice of Primary Endpoint  ................................ ................................ ....................... 20 
5. STUDY POPULATION  ................................ ................................ ............................. 20 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ........ 20 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......21 
5.3. Study  Population Diversity  ................................ ................................ ......................... 22 
6. STUDY INTERVENTION  ................................ ................................ ........................ 22 
6.1. Study Intervention(s) Administration  ................................ ................................ ......... 22 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 4 CONFIDENTIAL  6.1.1.  Study Intervention Description  ................................ ................................ ................... 22 
6.1.2.  Dosing and Administration  ................................ ................................ ......................... 22 
6.2. Preparation, Handling, Storage and Accountability  ................................ ................... 23 
6.2.1.  Acquisition and Accountability  ................................ ................................ .................. 23 
6.2.2.  Packaging and Labeling  ................................ ................................ .............................. 23 
6.3. Randomization and Blinding  ................................ ................................ ...................... 23 
6.4. Study Intervention Compliance  ................................ ................................ .................. 24 
6.5. Concomitant Therapy  ................................ ................................ ................................ .24 
7. STUDY INTERVENTION D ISCONTINUATION AND P ARTICIPANT 
DISCONTINUATION  ................................ ................................ ............................... 24 
8. STUDY PROCEDURES  ................................ ................................ ............................ 25 
8.1. Visit Pro cedures  ................................ ................................ ................................ .......... 25 
8.1.1.  Informed Consent  ................................ ................................ ................................ .......25 
8.1.2.  Medical History  ................................ ................................ ................................ .......... 26 
8.1.3.  Physical Examination  ................................ ................................ ................................ .26 
8.1.4.  Body Measurements and Resting Vital Signs  ................................ ............................ 26 
8.1.5.  Screening FLU -PRO  ................................ ................................ ................................ ...26 
8.1.6.  Randomization and Dispensing Study Medication  ................................ ..................... 27 
8.1.7.  Subject Instructions  ................................ ................................ ................................ ....27 
8.1.8.  Day 2 -7 Subject Contact  ................................ ................................ ............................. 28 
8.2. Laboratory Assessments  ................................ ................................ ............................. 28 
8.2.1.  Assessments in the Clinic  ................................ ................................ ........................... 28 
8.2.2.  Central Laboratory Assessments  ................................ ................................ ................ 28 
8.2.3.  Pharmacokinetics Assessments  ................................ ................................ .................. 29 
8.2.4.  Plan for Monitoring Viral Resistance  ................................ ................................ ......... 29 
8.3. Subject Diary  ................................ ................................ ................................ .............. 29 
8.3.1.  Subject Diary Completion  ................................ ................................ .......................... 29 
8.3.2.  Subject Diary Compliance Monitoring  ................................ ................................ .......30 
8.4. Adverse Events and Serious Adverse Events  ................................ ............................. 30 
8.4.1.  Definitions  ................................ ................................ ................................ .................. 30 
8.4.2.  Recording and Follow Up of Adverse Events  ................................ ............................ 31 
8.4.3.  Reporting Requirement  ................................ ................................ ............................... 31 
8.4.4. Management of Subjects Requiring Hospitalization  ................................ .................. 32 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 5 CONFIDENTIAL  8.4.5.  Medication Errors  ................................ ................................ ................................ .......32 
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ .......32 
9.1. Sample Size Determination  ................................ ................................ ........................ 32 
9.2. Efficacy Variables  ................................ ................................ ................................ ......33 
9.3. Response Definitions  ................................ ................................ ................................ ..34 
9.4. Statistical Methodology  ................................ ................................ .............................. 34 
9.4.1.  Efficacy Analyses  ................................ ................................ ................................ .......34 
9.4.2.  Population Pharmacokinetics Analysis  ................................ ................................ .......35 
9.4.3.  Safety Analyses  ................................ ................................ ................................ .......... 35 
10. OPERAT IONAL CONSIDERATIONS  ................................ ................................ .....36 
10.1.  Regulatory, Ethical and Study Oversight Considerations  ................................ .......... 36 
10.1.1.  Ethics  ................................ ................................ ................................ .......................... 36 
10.1.2.  Investigator Responsibilities  ................................ ................................ ....................... 36 
10.1.3.  Quality Assurance and Quality Control  ................................ ................................ ......37 
10.1.4.  Safety Oversight  ................................ ................................ ................................ ......... 37 
10.1.5.  Data Handling and Record Keeping  ................................ ................................ ........... 37 
10.1.6.  Clinical Monitoring  ................................ ................................ ................................ ....38 
10.1.7.  Protocol Deviations  ................................ ................................ ................................ ....38 
10.1.8.  Study Discontinuation and Closure  ................................ ................................ ............ 38 
10.1.9.  Data and Report Requirements  ................................ ................................ ................... 38 
10.1.10.  Confidentiality and Privacy  ................................ ................................ ........................ 39 
10.1.11.  Publication and Data Sharing  ................................ ................................ ..................... 39 
10.1.12.  Key Roles and Study Governance  ................................ ................................ .............. 39 
11. REFERENCES  ................................ ................................ ................................ ........... 40 
APPENDIX  1. PROTOCOL REVISION HI STORY  ................................ ................................ .43 
APPENDIX  2. CONTACT INFORMATION  ................................ ................................ ............ 49 
APPENDIX  3. LIST OF ESSENTIAL DO CUMENTS FOR THE SITE  ................................ ..50 
APPENDIX  4. TOXICITY GRADING TAB LES ................................ ................................ .....52 
APPENDIX  5. FLU -PRO DOMAIN/SUBDO MAIN STRUCTURE  ................................ ........ 59 
 
 
  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 6 CONFIDENTIAL  1. PROTOCOL SUMMARY  
1.1. Synopsis  
Title of Study:  A Phase 3, Randomized, Double -Blind, Placebo Controlled Trial to 
Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Mild 
or Moderate COVID -19 
Name of Test Drug:  Nitazoxanide 300 mg Tablets  
Name of Active  Ingredient:  Nitazoxanide  
Study Sponsor:  The Romark Institute for Medical Research  
IND Number:  149,166  
STUDY DETAILS  
Anticipated Study Period:  July 2020 – January 2021  
Protocol & Amendments:  Original Protocol , version 1.0 : July 14, 2020  
Amendment 1, version 2.0:  July 23, 2020  
Amendment 2, version 3.0:  September 16, 2020  
Amendment 3 , version 4.0: January 11, 2021  
Investigators:  Multiple in the US.  
OBJECTIVES  
Primary Objective:  To evaluate the effect of NTZ in reducing the time to Sustained Response 
compared to placebo in subjects  with mild or moderate COVID -19 
Secondary Objectives:  To evaluate the effect of NTZ in reducing the rate of progression to Severe 
COVID -19 Illness compared to placebo  
Exploratory Objectives:  To evaluate:  
i. The proportion of subjects positive for SARS -CoV -2 by Aptima® SARS -CoV -
2 Assay   at each of Days 4 and 10  
ii. The c hange from baseline in quantitative SARS -CoV -2 RNA measured by 
RT-PCR  at each of Days 4 and 10  
iii. The effect of NTZ in reducing  the rate of hospitalization compared to placebo  
iv. The effect of NTZ in reducing the rate of mortality compared to placebo  
Safety Objectives:  Safety will be assessed by analysis of adverse events.  
METHODOLOGY  
Study Design:  Multicenter, randomized, double -blind trial  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 7 CONFIDENTIAL  Treatments:  Subjects  will be  randomized 1:1 to one of the following groups:  
Group 1 (NTZ):  Two NTZ 300 mg tablets b.i.d. for 5 days 
administered orally with food.  
Group 2 (Placebo):  Two placebo tablets b.i.d. for 5 days  administered 
orally with food.  
Study Duration:  Subjects will receive  2 tablets b.i.d. for 5 days (10 doses). The follow up 
period will extend  through the end of study visit at study Day 28. 
SUBJECT POPULATION  
Number of Subjects Planned:  At least 350 up to 400 subjects with laboratory -confirmed SARS -CoV -2-
infection. This may require enrollment of up to 800 total subjects.  
Inclusion Criteria:  
1. Male or female at least 12 years of age  
2. [Criterion removed in protocol amendment 2. See Appendix 1  for revision history. ] 
3. Presence of clinical signs and/or symptoms consistent with worsening or stable mild or moderate 
COVID -19 (one of the following is required):  
a. Presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) wit h a 
score of ≥2 as determined by Screening FLU -PRO OR  
b. Presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a 
score of ≥2 as determined by Screening FLU -PRO with pulse rate ≥90 OR  
c. Presence of at least one respiratory  symptom domain (head, throat, nose, chest, cough) with a 
score of ≥2 as determined by Screening FLU -PRO with respiratory rate ≥16  
AND  patient reported assessment that symptoms are present, the symptoms are not consistent with the 
subject’s usual health, t he symptoms interfere with daily activities, and the symptoms have worsened 
or remained the same relative to the previous day, as confirme d by responses to questions in the 
Screening FLU -PRO.  
4. Onset of symptoms no more than 72 hours before enrollment in the  trial. Onset of symptoms is 
defined as the earlier of the first time at which the subject experienced subjective fever or any 
respiratory symptom (headache/head congestion, throat symptoms, nasal symptoms, chest 
symptoms, cough).  
5. Willing and able to provide written informed consent (including assent by legal guardian if under 
18 years of age) and comply with the requirements of the protocol, including completion of the 
subject diary and all protocol procedures.  
Exclusion Criteria:  
1. Persons with any cli nical sign or symptoms suggestive of severe systemic illness with COVID -19, 
including the following:  
a. shortness of breath at rest,  
b. resting pulse ≥125 beats per minute,  
c. resting respiratory rate ≥30 breaths per minute , or 
d. SpO 2 ≤ 93% on room air at sea level . 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 8 CONFIDENTIAL  2. Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, 
bronchitis or sinusitis or received antibiotics for these conditions within two weeks prior to and 
including study day 1.  
3. Severely immunodeficient persons inc luding:  
a. Subjects with immunologic disorders or receiving immunosuppressive therapy (e.g., for organ 
or bone marrow transplants, immunomodulatory therapies for certain autoimmune diseases)  
b. Subjects with untreated HIV infection or treated HIV infection with a CD4 count below 350 
cells/mm3 in the last six months  
c. Subjects actively undergoing systemic chemotherapy or radiotherapy treatment for 
malignancy  
d. Subjects using steroids as maintenance therapy for a chronic condition  
4. Subjects with active respiratory aller gies or subjects expected to require anti -allergy medications 
during the study period for respiratory allergies.  
5. Females of childbearing potential who are either pregnant or sexually active without the use of 
birth control.   
6. Subjects with a history of COV ID-19 or known to have developed anti -SARS -CoV -2 antibodies.  
7. Subjects residing in the same household with another subject participating in the study.  
8. Treatment with any investigational drug or vaccine therapy within 30 days prior to screening and 
willing t o avoid them during the course of the study.  
9. Receipt of any dose of NTZ within seven days prior to screening.  
10. Known sensitivity to NTZ or any of the excipients comprising the study medication.  
11. Subjects unable to swallow oral tablets or capsules.  
12. Subjects with known severe heart, lung, neurological or other systemic disease that the 
Investigator believes could preclude safe participation.  
13. Subjects likely or expected to require hospitalization unrelated to COVID -19 during the study 
period.  
14. Subjects taking me dications considered to be major CYP2C8 substrates.  Refer to Table 5  in 
Section 6.5. 
15. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the 
requirements of this protocol including completion of the subject diary.  
ASSESSMENTS  
Efficacy:  
 Subjects will complete a diary recording oral temperature twice daily and the FLU -PRO© 
patient reported outcomes instrument once daily in the evening for 21 days for efficacy 
evaluation.  
 Subjects will be contacted daily by site staff on study days 2 -7 to screen for progression to 
severe illness or other complications.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 9 CONFIDENTIAL  Virology: Nasopharyngeal swab samples will be collected on each of study Days 1, 4, and 10 for analysis 
of virology endpoints.  
Safety: The safety of study drug ad ministration will be monitored by assessment of adverse events from 
baseline through the Day 28 study exit, clinical laboratory testing at baseline and on Day 10, physical 
examinations and vital signs assessments at screening, Da y 10 and Day 22 and telepho ne monitoring/at 
home visits during Day 2 through Day 7 and Day 28 . 
Pharmacokinetics: On the morning of Day 4 prior to dosing, trough plasma samples will be collected.  
 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 10 CONFIDENTIAL  1.2. Schedule of Assessments  
Table  1: Schedule of Assessments  
Assessment  Screening  Baseline  Treatment 
Period  Diary 
Period  Follow -Up Visits  Unscheduled  
Day 1  Day 1  Day 2 -7 Day 1 -21 Day 4±1  Day 10±3  Day 2 2+3 Day 28+3  As Needed  
Signed informed consent/assent1 X         
Demographics, smoking & medical history2 X         
Urine pregnancy test7 X         
Physical examination3 X    X4 X4 X4  X4 
Body weight and resting vital signs5 X    X X X  X 
Complete Screening FLU -PRO6 X         
Evaluate eligibility7 X         
Collect nasopharyngeal swabs8  X   X X    
Collect blood sample for lab safety tests8  X     X  X 
Collect blood sample for antibody tests8  X     X   
Collect blood sample for pharmacokinetics8     X     
Collect urine sample for routine urinalysis8  X     X  X 
Record concomitant medications   X   X X X  X 
Randomize & dispense study medication9  X        
First dose and practice  diary in -office9,10  X        
Review/record adverse events11  X   X X X  X 
Instructions re: dosing, concomitant medications, diary 
completion, follow -up visits, and emergency care12  X X  X X X  X 
Contact subject to screen for complications   X13     X14  
Complete diary (subject responsibility)10    X      
Review subject diary entries  (site responsibility)15    X      
1 See Section 8.1.1  2 See Section 8.1.2  3 See Section 8.1.3  4 Completed as necessary, see Section 8.1.3  5 See Section 8.1.4  6 See Section 8.1.5  7 See Section 5.0   
8 See Section 8.2  9 See Section 8.1. 6 10 See Section 8.3.1  11 See Section 8. 4 12 See Section 8.1. 7 13 See Section 8.1. 8  14 See Section 8.1.9  
 15 See Section 8.3.2  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 11 CONFIDENTIAL  2. INTRODUCTION  
2.1. Coronavirus Disease 2019 (COVID -19) 
Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2), a novel betacoronavirus , was 
isolated in December 2019 from patients presenting with unidentified viral pneumonia ( Zhu et al. 
2020 ). As of early June 2020, the virus resulted in more than 7 million infections and nearly 
500,000 deaths worldwide ( Johns Hopkins Coronavirus Resourc e Center 2020 ).  
Infection with SARS -CoV -2 produces illness known as Coronavirus Disease 2019 or “COVID -
19”. Commonly reported symptoms include fever, chills, cough, shortness of breath, difficulty 
breathing, fatigue, muscle or body aches, headache, new lo ss of taste or smell, sore throat, 
congestion or runny nose, nausea, vomiting, and diarrhea ( U.S. CDC 2020 a). The severity of 
illness ranges from mild and self -limited to very severe or fatal, with the current U.S. 
hospitalization rate of 82 per 100,000 ca ses and 255 per 100,000 in those over 65 years of age 
(U.S. CDC 2020b ). 
Seroprevalence studies conducted in U.S. metropolitan areas have estimated between 5% and 14% 
population -level exposure to SARS -CoV -2, indicating that a significant proportion of the 
population is still at risk for a first infection ( Sood et al. 2020 , Goldberg 2020 ). Continued social 
distancing and “safer at home” measures  aimed at reducing transmission of the virus has resulted 
in record unemployment in the U.S., and the  SARS -CoV -2 pan demic is expected to result in a 
more than 10% reduction in U.S. domestic GDP in 2020  (OECD 2020 ). 
Remdesivir for intravenous administration has received emergency use authorization in the U.S. 
for hospitalized patients with COVID -19, but no antiviral has been authorized or approved for 
mild or moderate illness.  
2.2. Nitazoxanide (NTZ)  
NTZ is a thiazolide anti -infective with in vitro  activity against parasites, anaerobic bacteria, and 
viruses ( Anderson and Curran  2007 ). 
ALINIA® (NTZ) for Oral Suspension (patients 1 year of age and older) and ALINIA (NTZ) 
Tablets (patients 12 years and older) are marketed in the United States for the treatment of diarrhea 
caused by Giardia lamblia  or Cryptosporidium parvum .  ALINIA for Ora l Suspension and 
ALINIA Tablets have not been shown to be superior to placebo for the treatment of diarrhea caused 
by Cryptosporidium parvum  in HIV -infected or immunodeficient patients ( ALINIA Prescribing 
Information 2019 ). 
2.2.1.  NTZ Inhibits Viral Replication a nd Cytokine Secretion  
Tizoxanide, the active circulating metabolite of NTZ, has been shown to possess antiviral activity 
in cell culture against a broad range of viruses including influenza A and B viruses, coronaviruses 
(SARS -CoV -2, MERS -CoV , HCoV -229E, HCoV -OC43, HCoV -NL63 , canine CoV S -378, 
murine coronavirus, mouse hepatitis virus strain A59 (MHV -A59)), parainfluenza (Sendai) virus, 
RSV A -2, rotavirus, norovirus, hepatitis C virus genotypes 1a and 1b, Japanese encephalitis virus, 
dengue fever virus -2, yellow fever virus, hepatitis B virus, and human immunodeficiency virus 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 12 CONFIDENTIAL  (HIV) ( Rossignol 2014 , Rossignol 2016 , Wang et al. 2020 , Piacentini et al. 2018 , Romark data on 
file).  Experiments in HeLa R19 cells have shown that NTZ inhibits replication of rhinov irus A 
serotypes 2 and 16 (Romark Study Report RM01 -0434).  Concentrations of tizoxanide required to 
inhibit replication of these viruses by 50% (EC50s) were generally between 0.2 and 3 µM 
depending upon the test conditions.    
The anti -influenza activity of nitazoxanide and its circulating metabolite, tizoxanide, has been 
investigated in human (Monocytic U937, T -lymphocytic Jurkat, and Alveolar type II -like A549) 
and canine (MDCK) cells after infection with multiple different strains of influenza A virus 
including oseltamivir -resistant and amantadine -resistant strains ( Rossignol et al. 2009 , Ashton et 
al. 2010 , Sleeman et al. 2014 ).  In a study of the susceptibility of 210 circulating seasonal influenza 
viruses to tizoxanide demonstrated median EC50 values (±IQR) of 0.48 μM (0.33 -0.71), 0.62 μM 
(0.56 -0.75), 0.66 μM (0.62 -0.69), and 0.60 μM (0.51 -0.67) for A  (H1N1)pdm09, A  (H3N2), B  
(Victoria lineage) and B  (Yamagata lineage), respectively ( Tilmanis et al. 2017 ). 
Laboratory studies to evaluate the potential f or resistance of influenza A virus to tizoxanide have 
been unable to select for resistant virus (Romark Study Report RM01 -0417).  These studies suggest 
a low potential for resistance.  
Studies in peripheral blood mononuclear cells have also shown tizoxanide  suppresses secretion of 
pro-inflammatory cytokines that are upregulated by viral respiratory infection s (VRIs) .  
Concentrations required to suppress cytokine secretion by 50% for IL -2, IL -4, IL -5, IL -6, IL -8, 
IL-10 and TNF -α ranged from 2.0 to 9.8 µM ( Rossignol and van Baalen 2018 , Romark Study 
Report 9264).  Nitazoxanide has also been shown to suppress IL -6 production in thioglycollate 
broth -injected mice ( Hong et al. 2012 ). 
Ongoing studies of the mechanism of action of NTZ have shown NTZ and tizoxanide m odulate 
mitochondrial function by uncoupling oxidative phosphorylation.  Studies indicate tizoxanide 
decreases cellular ATP in a dose -dependent manner in MDCK cells and in MDCK cells infected 
with influenza viruses.  Maximum inhibition of ATP in influenza -infected or uninfected MDCK 
cells reaches up to 45% after 24 hours of exposure to 100 µM tizoxanide.  In these experiments, a 
10% reduction of ATP achieved by adding less than 10 µM tizoxanide is sufficient to inhibit 
influenza virus replication by approxi mately 90%.  The decrease in cellular ATP does not affect 
cell viability and is reversible after eliminating tizoxanide from the culture ( Rossignol and van 
Baalen 2018 ).  Studies of a number of different viruses have shown viral replication is ATP -
dependen t (Braakman et al. 1992 , Braakman et al. 1991 , Doms et al. 1987 , Chang et al. 2009 , 
Mirazimi and Svensson 2000 ).  In the case of NTZ, key viral proteins like hemagglutinin 
(influenza), F -protein (RSV and parainfluenza), and N protein (coronavirus) have been identified 
as potential end targets of this mechanism ( Rossignol et al. 2009 , Piacentini et al. 2018 , Cao et al. 
2015 ).  In addition, inhibition of ATP and its downstream effect on AMP -activated protein kinase 
activation has been shown to suppress sec retion of pro -inflammatory cytokines ( Lee et al. 2017 , 
Sag et al. 2008 , Wang et al. 2003 ). 
The activity of NTZ in inhibiting replication of a broad range of respiratory viruses as well as the 
secretion of pro -inflammatory cytokines upregulated during respi ratory virus infection has 
prompted clinical development of NTZ for treatment or prophylaxis of respiratory illness caused 
by VRIs.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 13 CONFIDENTIAL  2.2.2.  Pharmacokinetics of NTZ in Humans  
NTZ is not detectable in the plasma following oral administration of the drug.  The main 
metabolites of NTZ in humans are tizoxanide and tizoxanide glucuronide.  Tizoxanide is highly 
bound to plasma proteins (>99%).  The absorption of NTZ in immediate release tablets is 
significantly enhanced (Cmax and AUC of tizoxanide and tizoxanide glucuroni de in plasma are 
more than doubled) when it is administered with food.  In fasted human volunteers receiving a 
single 500 mg dose of 14C NTZ, approximately one -third of the dose was excreted in urine as 
tizoxanide and tizoxanide glucuronide, and two -thirds  was excreted in feces as tizoxanide.  No 
other significant metabolites were detected (NTZ 300 mg Tablets Investigators Brochure).  
The pharmacokinetics of tizoxanide and tizoxanide glucuronide during repeated oral dosing of 
NTZ 300 mg extended release tabl ets administered 600 mg twice daily with food were evaluated 
in healthy volunteers.  Twelve (12) subjects received two NTZ controlled release tablets twice 
daily with food for 7 days.  The pharmacokinetics were studied in plasma up to 12 hours post -dose 
after the morning dose on Day 1 and Day 7, and before the morning dose on Day 2 -6.  Based on 
mixed effect analysis of variance, the steady state tizoxanide and tizoxanide glucuronide plasma 
concentrations was reached by Day 2, after one day of treatment with  NTZ at 600 mg b.i.d.  The 
main pharmacokinetics parameters of tizoxanide and tizoxanide glucuronide are summarized in 
the table below:  
Table  2: Summary of Tizoxanide and Tizoxanide Glucuronide Pharmacokinetics 
Parame ters 
PK Parameter (unit)  Tizoxanide  Tizoxanide Glucuronide  
 Day 1  
N=12  Day 7  
N=12  Day 1  
N=12  Day 7  
N=12  
Cmax (µg/mL)  5.23 ± 2.71  8.16 ± 4.16  4.88 ±1.72  8.96 ±3.48  
tmax (h)  6.00 (4.00 -9.00)  5.00 (3.00 -8.00)  6.00 (5.00 -11.00)  5.50 (0.00 -7.02)  
tlag (h)  0.00 (0.00 -2.00)  0.00 (0.00 -0.00)  0.50 (0.00 -2.00)  0.00 (0.00 -0.00)  
AUC0 -t (µg.h/mL)  26.9  ± 16.1  52.5 ± 33.7  29.5  ± 12.1  75.0 ± 37.8  
AUC0 - Τ (µg.h/mL)  28.6  ± 16.3a 48.3 ± 31.9b 30.5  ± 12.2c 75.2 ± 37.9  
C Τ (µg/mL)  0.709 ± 0.987  1.72 ± 2.04  1.39 ± 0.846  3.89 ± 2.88  
AUC0 -∞ (µg.h/mL)  27.8 ± 17.8b 52.3 ± 35.6b 35.3 ± 16.5d 62.1 ± 24.2e 
t1/2 (h)  1.66 ± 0.408b 2.19 ± 0.485b 2.70 ± 0.848c 4.99 ± 5.20  
λz (1/h)  0.441 ± 0.106b 0.331 ± 0.0733b 0.282 ± 0.0902c 0.201 ± 0.0813  
Cavg (µg/mL)  NA 4.02 ± 2.66b  NA 6.27 ± 3.16  
Cmin (µg/mL)  NA 1.50 ± 1.83  NA 3.63 ± 3.00  
PTF (%)  NA 193 ± 39.1b  NA 101 ± 40.7  
Swing (%)  NA 1039 ± 656  NA 268 ± 194  
Values are arithmetic mean ± SD, except median (range) for t max and t lag 
N = number of subjects with data; NA = not applicable  
a N=10; b N=11; c N=11; d N=8; e N=7 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 14 CONFIDENTIAL   
Table  3: Summary of Tizoxanide and Tizoxanide Glucuronide Trough Plasma 
Concentrations  (µg/mL) by Study Day  
Analyte  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  
Tizoxanide  0.709  
(139)  1.55 
(100)  2.36 
(101)  3.24 
(100)  3.80 
(146)  3.26 
(119)  3.02  
(99) 
Tizoxanide 
Glucuronide  1.39  
(61) 3.68  
(72) 4.38 
(73) 5.35 
(77) 5.83 
(99) 5.94 
(91) 5.65 
(69) 
 
2.2.3.  Overview of Clinical Experience with NTZ  
NTZ has been marketed for diarrheal disease caused by Giardia  or Cryptosporidium  in the United 
States since 2003 and in Latin America since 1996.  It is estimated that more than 350 million 
patients have been exposed to NTZ worldwide.  No drug -related seri ous adverse events have been 
reported during post -marketing experience with NTZ.  
Over 7,500 subjects have been treated with NTZ in clinical trials, including 3,147 subjects 12 years 
of age and older who have been exposed to the NTZ 300 mg extended release tablets (as 
monotherapy, n = 2,659, or in combination with oseltamivir, n = 488).  Of the 3,147 subjects, 
2,659 were given a dose of 600 mg twice daily for 5 days.  The most commonly (at least 2% of 
treated subjects) reported adverse events (AEs) regardles s of causality assessment were: 
chromaturia (10.8%), diarrhea (6.3%), abdominal pain/abdominal pain upper/abdominal pain 
lower (2.8%), bronchitis (2.8%), nausea (2.7%), and headache (2.3%).  In the placebo -controlled 
trials, the rates of occurrence of AEs did not differ significantly from those of placebo except for 
chromaturia (10.8% compared to 0.8% for placebo).  Less than 1% of subjects discontinued 
therapy because of AEs ( NT-300 Investigators Brochure -COVID/VRI ). 
2.2.4.  Clinical Experience with NTZ in Treatme nt of Coronaviruses  
Fifty -two (52) coronavirus -infected subjects meeting the criteria proposed by this protocol were 
enrolled in study RM08 -3004, a study of NTZ in the treatment of influenza. The FLU -PRO 
instrument was administered daily for 21 days . The N TZ group experienced a treatment benefit of 
101 hours at the median in Time to Sustained Response [Median (IQR): 101.3 (58 -250) for the 
NTZ group and 201.8 (117 ->504) for the placebo group, p=0.0932]. See Figure 1 for Kaplan -
Meier curves of Time to Sustain ed Response for this population.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 16 CONFIDENTIAL  Safety Objectives:  Safety will be assessed by analysis of adverse events.  
4. STUDY DESIGN  
4.1. Study Design Overview  
This study is a multicenter, randomized, double -blind, placebo -controlled trial designed to 
evaluate efficacy and safety of NTZ 600 mg administered orally twice daily for five days compared 
to a placebo for the treatment of mild or moderate COVID -19. 
Subje cts will be stratified according to the following criteria:  
Severity of COVID -19 Illness:  • Mild illness  defined as  baseline assessments of (1)  at 
least one respiratory domain* with a baseline score 
≥2 and (2) resting pulse <90 beats per minute and (3) 
resting respiratory rate < 20 breaths per minute.  
• Moderate illness  defined as baseline assessments of 
(1) at least one respiratory domain* with a baseline 
score ≥2 and either (2) resting pulse ≥90 beats per 
minute or (3) resting respiratory rate ≥ 20 breaths per 
minute.  
* For this purpose, respiratory domains shall include the 
following 5 FLU -PRO domains/subdomains: chest, cough, 
nose, throat and head.  
Time from onset of symptoms to  
randomization :  <36 hours/≥ 36 hours  
Risk of severe illness (per  CDC ):  • At Increased Risk:  Subjects with COPD, Type 2 
diabetes mellitus, obesity (BMI ≥30), chronic kidney 
disease, sickle cell disease, serious heart conditions 
(such as heart failure, coronary artery disease, or 
cardiomyopathies) , asthma (moderate or severe), 
cerebrovascular disease, cystic fibrosis, hypertension 
or high blood pressure, immunocompromised state 
(due to immune deficiencies, HIV, use of 
corticosteroids, or use of other immune -weakening 
medications), neurologic conditi ons (e.g., dementia), 
liver disease, pulmonary fibrosis, past or present 
history of smoking, thalassemia, or type 1 diabetes 
mellitus.  Subjects who are ≥65 years of age.  
• Not At Increased Risk:  Subjects with none of the 
above conditions  
Within strata, sub jects will be randomized 1:1 to one of the following groups:  
• Group 1 (NTZ):   Two NTZ 300 mg tablets b.i.d. for 5 days  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 17 CONFIDENTIAL  • Group 2 (Placebo):  Two placebo tablets b.i.d. for 5 days  
The study is expected to take place from July 2020 through Janua ry 2021 . 
We expect that a large number of subjects enrolled will be positive for Enterovirus/Rhinovirus 
(EV/RV). Efficacy and safety data for subjects who are positive for EV/RV at Baseline will be 
analyzed as part of concurrently enrolling study RM08 -3009 . 
4.2. Rationale for Important Issues in the Study Design  
4.2.1.  Choice of NTZ Dose and Duration of Treatment  
The dose of NTZ used for this clinical trial (600 mg b.i.d. for 5 days) has been associated with 
reductions in durations of illness in subjects infected with influenza, Enterovirus/Rhinovirus , and 
coronavirus . Dose -range -finding study RM08 -3001 in subjects with influenza infection 
demonstrated a dose -dependent efficacy response with a 300 mg b.i.d. group demonstrating a non -
significant improvement over placebo.  
In clinical trials involving 2, 659 subjects, adverse events reported by subjects receiving  600 mg 
NTZ b.i.d. for 5 days were similar to those of subjects receiving the placebo,  with the exception 
of a higher rate of  chromaturia (10.8% compared to 0.8% for the placebo) . Studies of NTZ at 
higher doses have shown dose -dependent increases in the frequency  of reported diarrhea and other 
gastrointestinal side effects, therefore no higher dose is  planned for this study.  
SAR S-CoV -2 virus titer is believed to peak between the onset of symptoms  and symptomatic day 
4 and is not able to be cultured after seven days of symptoms ( Wölfel et al. 2020 ). Antiviral  
treatment will have a reduced magnitude of treatment benefit when the ho st immune response is 
effectively decreasing the infectious viral load. Further, a study of remdesivir comparing 5 - and 
10-day courses of treatment found no difference between the two in patients with severe COVID -
19 (Goldman et al. 2020 ). Therefore, it is  unlikely that a course of treatment beyond five days will 
confer any significant additional benefit.   
4.2.2.  Choice of Duration of Follow Up  
A 28-day (+3 days) study duration is proposed, including five days on treatment and approximately 
23 days of safet y and symptom follow -up. As previously described, SARS -CoV -2 virus titer is 
believed to peak between the onset of symptoms and symptomatic day 4 and is not able to be 
cultured after seven days of symptoms  (Wölfel et al. 2020 ). Further, onset of Acute Respi ratory 
Distress Syndrome (ARDS) in patients infected with SARS -CoV -2 is approximately 8 -12 days ( Li 
and Ma 2020 ). Therefore, 28 days is expected to be a sufficient period of time to capture resolution 
of viral shedding  and any hospitalizations or severe complications of illness. Any adverse events 
ongoing at the time of the Day 28 visit will be followed to resolution.  
4.2.3.  Choice of Control Group  
A placebo control is appropriate for the study due to lack of any approved active control.  
4.2.4.  Choice of Patient Population  
The population to be studied includes adults and adolescents with mild or moderate illness 
consistent with SARS -CoV -2 infection. Because there are no approved antivirals for the treatment 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 18 CONFIDENTIAL  of mild or moderate COV ID-19 in outpatients , subjects will not be prevented from being 
prescribed rescue medication for complications if warranted. Therefore, participation in the study 
will not pose unreasonable risk to any eligible subject. Discussion of specific eligibility c riteria is 
presented below.  
4.2.4.1.  Choice of Signs and Symptoms Required for Inclusion  
Data from studies RM08 -3004 and RM08 -3005 indicate that, in subjects infected with influenza, 
EV/RV  or seasonal coronavirus, subjects with low symptom scores for the head, thro at, nose, chest 
and cough symptom domains in the absence of elevated pulse or respiratory rate, illness may be 
expected to resolve quickly. These subjects have less opportunity to benefit from antiviral 
treatment . Further, subjects who indicate that sympto ms are already improving are also unlikely 
to benefit from treatment. Therefore, subjects will be required to have a score of ≥2 for two 
respiratory symptom domains (head, throat, nose, chest, or cough) or a score of ≥2 for one 
respiratory symptom domain i n the presence of elevated vital signs (pulse ≥90 beats per minute or 
respiratory rate ≥16 breaths per minute).  Subjects will be excluded if they report having no 
symptoms (global assessment), being at their usual health, that their symptoms do not interfe re 
with their usual activities, or that their symptoms have improved since yesterday.  Subjects 
presenting with signs or symptoms consistent with severe COVID -19 (resting shortness of breath, 
resting pulse ≥125, resting respiratory rate ≥30) will also be ex cluded from the study.  
4.2.4.2.  Inclusion of Subjects At Least 12 Years of Age (No Upper Age Limit)  
The population to be studied includes adults and adolescents at least 12 years of age with mild or 
moderate COVID -19. This is a population similar to those selected for studies RM08 -3001, RM08 -
3002, RM08 -3003 , RM08 -3004  and RM08 -3005  of the NTZ 300 mg extended release tablets in 
more than 5,000 subjects with  colds or  influenza -like illness. No safety concerns have been 
identified from these clinical trials. Data from pharmacokinetics studies in healthy volunteers 12 
to 17 years of age or 18 to 65 years of age indicate that the pharmacokinetics of the major NTZ 
metabolites, tizoxanide and tizoxanide glucuronide, following oral administration of a NTZ 500 
mg tablet are s imilar for these age groups. Safety data is also similar for these age groups. 
Therefore, the adult dose is deemed appropriate for pediatric patients down to 12 years of age. 
Informed consent will be required for subject participation in this study (see Section 8.1.1 ). A 
signed assent form will be required for any minors enrolled (≤ 18 years of age or as local 
regulations apply) as well as signed parental/legal guardian consent by their parent/legal guardian 
allowing for the minor’s participation.  
4.2.4.3.  Inclusion  of Subjects with Underlying Conditions  
For the present study, some subjects (e.g., subjects >65 years of age, underlying asthma or COPD, 
diabetes mellitus, underlying cardiovascular disease, etc. – see Inclusion/Exclusion criteria ) who 
are at higher risk of complications or exacerbations of underlying conditions will be allowed to 
participate if, in the judgment of the investigator, they are able to comply with protocol 
requirements and are not expected to require hospitalization. There is no approved anti viral for 
mild or moderate COVID -19, and subjects will not be prevented from being prescribed rescue 
medication for complications. Therefore, participation in the study will not pose unreasonable risk 
to any eligible subject.   
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 19 CONFIDENTIAL  The pharmacokinetics of the p roposed dose of NTZ have been studied in subjects with renal and 
hepatic impairment and no dose adjustment is recommended in these populations. A thorough QTc 
study of NTZ at doses of 675 mg and 2700 mg found no prolongation of the QTc interval.  
CYP450 inh ibition assays indicate that tizoxanide inhibits CYP2C8 with an IC 50 of 4.3µM , but a  
mechanistic static model used for potential drug -drug intera ctions indicated that a clinical 
interaction stemming from CYP2C8 inhibition by  tizoxanide  is unlikely.  
While tizoxanide is more than 99.9% bound to plasma proteins, a n in vivo drug-drug interaction 
study found no interaction between NTZ and warfarin. Tizoxanide inhibits the BCRP transporter 
and therefore may affect the pharmacokinetics of BCRP substrates , such as  rosuvastatin . Co-
administration of NTZ and rosuvastatin for seven days  led to a 40% increase in the C max of 
rosuvastatin and 80% and 70% increases of rosuvastatin AUC 0-t and AUC 0-∞, respectively.  
However, the short duration of treatment in this study is not anticipated to cause adverse effects 
related to co -administration of NTZ and rosuvastatin.  
For more  detailed information, refer to the NT -300 Investigator’s Brochure -COVID/VRI.  
4.2.4.4.  Exclusion of Subjects with Significant Immunodeficiency  
Individuals with significant immunodeficiency, such as patients undergoing chemotherapy, 
transplant recipients receiving immunosuppressive therapy, and HIV patients with very low CD4 
counts are more susceptible to lo nger durations of illness and more likely to experience 
complications due to viral respiratory infections. This is an important population in which to study 
antiviral drugs for the treatment of viral respiratory infections. Nonetheless, these subjects will  be 
excluded from the present study due to (1) the likelihood of longer viral shedding necessitating 
longer courses  or higher doses  of treatment than what is  proposed in this study, and (2) the 
likelihood that symptoms of illness may present differently in  immunocompromised persons 
compared to immunocompetent persons due to reduced ability to produce the immune response 
that results in symptoms  (van der Vries et al. 2013 , St. Jude Children’s Research Hospital ).  
4.2.5.  Use of Vitamin B Complex Supplement  
All subje cts will receive a vitamin B  complex supplement (Super B -Complex™, Igennus 
Healthcare Nutrition, Cambridge,  UK) one tablet twice a day with study medication. This dose 
follows the  manufacturer’s labeled dosing. The purpose of the supplement is to help mask  any 
chromaturia attributed to NTZ and aid in maintaining study blinding. The supplement  will supply 
each subject with the following Percent Daily Values based on a 2,000  calorie diet: vitamin B1 
1,333%, vitamin B2 824%, vitamin B3 240%, vitamin B5  360%, vitamin B6 1000%, vitamin B7 
100%, vitamin B12 15,000%, folate 100%, and  vitamin C 267%. Considering this supplement will 
provide well beyond the needed  daily allowance of these water -soluble vitamins, excess amounts 
are expected to be excreted in the urin e and provide discoloration.   
4.2.6.  Choice of Patient -Reported Outcome Instrument  
This clinical trial will use the InFLUenza Patient -Reported Outcome Questionnaire (FLU -PRO©).  
FLU -PRO© was developed with the support of the U.S. Department of Health and Human Se rvices 
through the National Cancer Institute and the National Institutes of Allergy and Infectious 
Diseases, National Institutes of Health, in response to the need for improved metrics to evaluate 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 20 CONFIDENTIAL  treatment effect in clinical trials of drugs for the treatm ent of influenza and other respiratory tract 
viral diseases.  It was developed and validated in accordance with FDA’s guidance, “Patient -
Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.”  
It has also been validated for use on an electronic device as part of an electronic diary (“eDiary”) 
that can time stamp diary entries to ensure timely recording, thereby mitigating risks of recall bias.  
We will use an electronic diary for this clinical trial.  FLU -PRO© was separat ely validated for use 
in a population with non -influenza like illness and also has recently been used in vaccine studies 
with older adults for the prevention of RSV ( Powers et al. 2018 , Yu et al. 2020 ). Data from Romark 
studies RM08 -3004 and RM08 -3005 also  indicates validity and ability to detect change in patients 
infected with Enterovirus/Rhinovirus  or seasonal coronavirus.  
4.2.7.  Choice of Primary Endpoint  
The primary endpoint was developed using data collected from 1,467 subjects infected with 
influenza, Enter ovirus/Rhinovirus  or seasonal coronavirus es during Romark studies RM08 -3004 
and RM08 -3005.  The endpoint defines a level of symptom improvement that constitutes a 
meaningful within -patient change in health status . The determination of m eaningfulness was based 
on empiric evidence derived from the use of anchor questions.  The endpoint requires (1) oral 
temperature <100.4  ºF, (2) reduction of total symptom severity score from the previous day , (3) 
the patient to provide confirmation that symptoms are at least somewhat better,  and (4) no 
symptom domain increase except below background levels for the remainder  of the study  
(sustained response) . These b ackground levels were de rived  based on symptom scores  reported by 
patients  at the time they also reported being a t usual health.  
5. STUDY POPULATION  
5.1. Inclusion Criteria  
1. Male or female outpatients at least 12 years of age  
2. [Criterion removed in protocol amendment 2. See Appendix 1  for revision history. ] 
3. Presence of clinical signs and/or symptoms consistent with  worsening or stable  mild or 
moderate COVID -19 (one of the following is required):  
a. Presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) 
with a score of ≥2 as determined by Screening FLU -PRO OR  
b. Presence of at least one  respiratory symptom domain  (head, throat, nose, chest, cough) with 
a score of ≥2 as determined by Screening FLU -PRO with pulse rate ≥90 OR  
c. Presence of at least one  respiratory symptom domain  (head, throat, nose, chest, cough) with 
a score of ≥2 as determine d by Screening FLU -PRO with respiratory rate ≥16  
AND  patient reported assessment that symptoms are present, the symptoms are not consistent 
with the subject’s usual health, the symptoms interfere with daily activities, and the symptoms 
have worsened or remained the same relative to the previous day, as conf irmed by responses 
to questions in the Screening FLU -PRO.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 21 CONFIDENTIAL  4. Onset of symptoms no more than 72 hours before enrollment in the trial. Onset of symptoms 
is defined as the earlier of the first time at which the subject experienced subjective fever or 
any respira tory symptom ( head, throat, nose, chest , or cough  symptoms ). 
5. Willing and able to pro vide written informed consent (including assent by legal guardian if 
under 18 years of age) and comply with the requirements of the protocol, including completion 
of the su bject diary and all protocol procedures.  
5.2. Exclusion Criteria  
1. Persons with any clinical sign  or symptoms suggestive of severe systemic illness with COVID -
19, including the following:  
a. shortness of breath at rest,  
b. resting pulse ≥125 beats per minute,  
c. resting respiratory rate ≥30 breaths per minute , or 
d. SpO 2 ≤ 93% on room air at sea level . 
2. Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, 
bronchitis or sinusitis or received antibiotics for these conditions wi thin two weeks prior to 
and including study day 1.  
3. Severely immunodeficient persons including:  
a. Subjects with immunologic disorders or receiving immunosuppressive therapy (e.g., for 
organ or bone marrow transplants, immunomodulatory therapies for certain au toimmune 
diseases)  
b. Subjects with untreated HIV infection or treated HIV infection with a CD4 count below 
350 cells/mm3 in the last six months  
c. Subjects actively  undergoing systemic chemotherapy or radiotherapy treatment for 
malignancy  
d. Subjects using steroids as maintenance therapy for chronic conditions  
4. Subjects with active  respiratory allergies or subjects expected to require anti -allergy 
medications during the study period for respiratory allergies.  
5. Females of childbearing potential who are either p regnant or sexually active without the use of 
birth control.  Female subjects of child -bearing potential that are sexually active must have a 
negative baseline pregnancy test and must agree to continue an acceptable method of birth 
control for the duration  of the study and for 1 month post -treatment.  A double barrier method, 
oral birth control pills administered for at least 2 monthly cycles prior to study drug 
administration, an IUD, or medroxyprogesterone acetate administered intramuscularly for a 
minimu m of one month prior to study drug administration are acceptable methods of birth 
control for inclusion into the study.  Female subjects are considered of childbearing potential 
unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if 
laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular 
ligation or bilateral oophorectomy.  
6. Subjects with a history of COVID -19 or known to have developed anti -SARS -CoV -2 
antibodies.  
7. Subjects residing in the s ame household with another subject participating in the study.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 22 CONFIDENTIAL  8. Treatment with any investigational drug or vaccine therapy within 30 days prior to screening 
and willing to avoid them during the course of the study.  
9. Receipt of any dose of NTZ within seven da ys prior to screening . 
10. Known sensitivity to NTZ or any of the excipients comprising the study medication.  
11. Subjects unable to swallow oral tablets or capsules.  
12. Subjects with known severe heart, lung, neurological or other systemic disease that the 
Investigator believes could preclude safe participation.  
13. Subjects likely or expected to require hospitalization unrelated to COVID -19 during the study 
period.  
14. Subjects taking medications considered to be major CYP2C8 substrates. Refer to  Table 5 in 
Section  6.5. 
15. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the 
requirements of this protocol including completion of the subject diary.  
5.3. Study Population Diversity  
The Sponsor will select clinical sites to support recruitment o f a diverse and representative 
population, including older individuals and racial and ethnic minorities.  
6. STUDY INTERVENTION  
6.1. Study Intervention(s) Administration  
6.1.1.  Study Intervention Description  
NTZ 300 mg extended release tablets for use in this study are yellow, round, convex, film -coated, 
bi-layer tablet s for oral administration, each tablet contains 300 mg of NTZ and the inactive 
ingredients.  
Placebo tablets will have the same appearance and inactive ingredients as the active NTZ 300 mg 
extended release  tablet . 
The vitamin B complex supplement is Super B -Complex™ manufactured by Igennus Healthcare 
Nutrition, Cambridge, UK.  The supplement will supply each subject with the following Percent 
Daily Values based on a 2,000 -calorie diet: vitamin B1 1,333%, vi tamin B2 824%, vitamin B3 
240%, vitamin B5 360%, vitamin B6 1000%, vitamin B7 100%, vitamin B12 15,000%, folate 
100%, and vitamin C 267%.  
6.1.2.  Dosing and Administration  
Group 1 (NTZ):  Subjects will receive two NTZ 300 mg tablets b.i.d. with food (< 1 hour after  
food intake) and a B complex vitamin (Super B -Complex™, Igennus 
Healthcare Nutrition, Cambridge, UK)  b.i.d. for 5 days  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 23 CONFIDENTIAL  Group 2 (Placebo):  Subjects will receive two placebo tablets b.i.d. with food (< 1 hour after food 
intake) and a B complex vitamin (Supe r B-Complex™, Igennus Healthcare 
Nutrition, Cambridge, UK)  b.i.d. for 5 days  
The food prior to drug intake should preferably be a high -fat meal, but at minimum a cereal bar.  
All subjects will receive a vitamin B complex supplement one tablet twice a day (m anufacturer’s 
labeled dosing) to help mask any potential chromaturia attributed to NTZ and aid in maintaining 
study blinding.  
6.2. Preparation, Handling, Storage and Accountability  
6.2.1.  Acquisition and Accountability  
Study medication will be provided by the Sponsor to the Investigational Site for dispensing.  
Drug accountability will be tracked using an IWRS/IRT system as described in the study -specific 
Data Management Plan. Unused supplies must be returned to the Sponsor or destroyed in 
accordance with institutional procedures in effect at the study Site.  
6.2.2.  Packaging and Labeling  
NTZ or placebo tablets will be packaged in white 30 cc HDPE bottles, each containing 20 tablets. 
The kits will be stored at room temperature and will bear labels with the following information:  
Table  4: Study Medication Label  
20 Tablets  Study No. RM08 -3008  Treatment No: XXXX  
Lot No: XXXX  
 
Take 2 Tablets by Mouth with Food  Twice Daily  
Caution: New Drug – Limited by Federal Law to Investigational Use  
STORE AT  ROOM TEMPERATURE • DO NOT USE BEYOND END OF STUDY  
KEEP OUT OF REACH OF CHILDREN  
Study Sponsor: The Romark Institute for Medical Research  
 
 
6.3. Randomization and Blinding  
Subjects will be randomized 1:1 to receive either NTZ or placebo.  An independent third party will 
prepare a master randomization list and maintain the masking of the study.  Subjects who qualify 
for the study will be assigned to treatment using centralize d randomization procedures.  The 
treatment numbers will appear on the bottles containing the masked study medication.  The 
randomization list will be masked to study participants including Sponsor, Investigators, study 
monitors, statisticians, subjects and  laboratory personnel.  Unmasking procedures will be detailed 
in the Medical Monitoring Plan and Investigators will be provided instructions for unmasking.  

Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 24 CONFIDENTIAL  6.4. Study Intervention Compliance  
Subject compliance with study medication will be checked by site staff  daily during the treatment 
period. Subjects will return the treatment kit with any unused medication to the clinic at the Day 
10 visit. Subjects will be considered non -compliant (major protocol deviation) if they have missed 
more than two doses of the stu dy medication during the first three days of the study. Non -
compliance will not be cause for discontinuation of subject participation in the study.  
6.5. Concomitant Therapy  
The following medications will not be allowed during the study: topical or systemic deco ngestants, 
nasal corticosteroids, and any prescription or non -prescription medications classified as (i) 
expectorants and cough preparations, (ii) analgesics and antipyretics , (iii) antihistamines 
(American Hospital Formulary Service (AHFS) classification)  or (iv) medications considered 
major CYP2C8 substrates (see Table 5  below) . As an exception to this rule, subjects will be 
allowed to use acetaminophen and/or dextromethorphan as necessary for disabling symptoms.  
Table  5: Major CYP2C8 Substrates  
Generic Name  Brand Name(s)  Therapeutic Use and/or Drug Class  
Amodiaquine  BASOQUIN, CAMOQUIN, 
FLAVOQUIN  Antimalarial  
Daprodustat (GSK1278863)  * Antianemic, prolyl hydroxylase 
inhibitor  
Dasabuvir (ABT -333) EXVIERA  Antiviral, NSB5 inhibitor  
Enzalutamide  XTANDI  Anticancer, antiandrogen  
Montelukast  SINGULAIR  Antiasthmatic, LTRA  
Pioglitazone  ACTOS  Antidiabetic, PPAR -γ agonist  
Repaglinide  NOVONORM, PRANDIN  Antidiabetic, meglitinide analog  
Source: Backman et al. 2016  
*Currently  listed as investigational only and not yet granted a trade name by the manufacturer  
Subjects are also prohibited from taking hydroxychloroquine, chloroquine, remdesivir , 
azithromycin  or lopinavir/ritonavir during the study except as standard -of-care resc ue medication.  
Medications for pre -existing conditions that are not excluded (see exclusion criteria) should be 
continued as prescribed.  Standard -of-care rescue medication is permitted for complications of 
COVID -19 illness.  The use of such medication will be recorded in the EDC system.  
7. STUDY INTERVENTION D ISCONTINUATION AND 
PARTICIPANT DISCONTI NUATION  
Treatment will be discontinued for individual subjects for the following reasons:  
1. An allergic reaction occurs or is suspected.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 25 CONFIDENTIAL  2. Medical conditions that may req uire study  medication  discontinuation in the Investigator’s 
judgment.  
3. Subject desire to discontinue participation.  
In the case of an allergic reaction or other medical condition requiring subject discontinuation, 
appropriate treatment will be instituted by  the Investigator.  
Subjects will be encouraged to complete all protocol -specified follow -up visits even if study drug 
is withdrawn.  
8. STUDY PROCEDURES  
8.1. Visit Procedures  
Study procedures to be completed at each visit are indicated in the Schedule of Assessment s. 
Descriptions of selected procedures are outlined in the following sections.  
8.1.1.  Informed Consent  
Each subject must give written consent according to local requirements after the nature of the study 
has been fully explained.  The informed consent form (ICF) must be signed before performance of 
any study -related activity.  The informed consent form will be approved by both the Sponsor and 
by the reviewing IRB.  They will be in accordance with principles that originated in the Declaration 
of Helsinki, current I CH and GCP guidelines, applicable regulatory requirements, and Sponsor 
policy.  
Before enrollment in the study, the Investigator or an authorized member of the investigational 
staff must explain to potential subjects the aims, methods, reasonably anticipate d benefits, and 
potential hazards of the study, and any discomfort participation in the study may entail.  Subjects 
will be informed that their participation is voluntary and that they may withdraw consent to 
participate at any time.  They will be informed  that choosing not to participate will not affect the 
care he/she will receive.  Finally, they will be told that the Investigator will maintain a subject 
identification register for the purposes of long -term follow -up if needed and that their records may 
be accessed by health authorities and authorized Sponsor staff without violating the confidentiality 
of the subject, to the extent permitted by the applicable law(s) or regulations.  By signing the ICF 
the subject is authorizing such access, and agrees to a llow his or her study physician to re -contact 
the subject for the purpose of obtaining consent for additional safety evaluations, if needed. Only 
subjects who are fully able to understand the risks, benefits, and potential AEs of the study, and 
provide the ir consent voluntarily will be enrolled.  
The subject will be given sufficient time to read the ICF and the opportunity to ask questions.  
After this explanation and before entry into the study, consent should be appropriately recorded 
by means of the subject's personally dated signature.  After having obtained the consent, a copy of 
the ICF must be given to the subject.  
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which inclu des reading and explaining all written information) and 
should personally date and sign the ICF after the oral consent of the subject is obtained, if permitted 
by local law.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 26 CONFIDENTIAL  Assent from any minor (≤ 18 years of age or as local regulations apply) enrolled i nto the study will 
be obtained along with documented consent from their parent/legal guardian to allow the minor to 
participate in the study.  The assent and consent forms must be signed prior to the performance of 
any study related activity.   
Signed ICFs  must remain in the subject's file(s) and be available for verification by representatives 
of Romark, the IRB, and FDA/relevant regulatory agencies at any time.   
8.1.2.  Medical History  
All relevant medical history should be entered in the EDC system at the Screening visit. Relevant 
medical history includes:  
1. Any disease, condition or surgery active at the time of the Screening visit;  
2. Any disease, condition or surgery ending within two months of the Screening visit; or  
3. Any other disease, condition or surgery r elevant to the subject’s infection or clinical 
management.  
8.1.3.  Physical Examination  
Physical examinations will include assessment of each body system including skin, head  (eye, ear 
and nose) , neck, mouth/throat, lymph nodes, cardiovascular, respiratory, gastro intestinal, 
neurological, and musculoskeletal systems as well as general appearance for abnormalities.  
The Investigator will complete a  full physical examination at the Screening visit. Physical 
examinations should occur at follow -up and unscheduled visits  as required by symptoms or 
adverse changes from baseline.  
8.1.4.  Body Measurements and Resting Vital Signs  
Body measurements and resting vital signs will include assessment of the following:  
1. Height (Screening visit only)  
2. Weight  
3. Oral temperature  
4. Blood pressure  
5. Pulse rate  
6. Respiratory rate  
7. Oxygen saturation  
8.1.5.  Screening FLU -PRO  
The FLU -PRO questionnaire will be administered during the Screening visit to confirm 
symptoms required for eligibility.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 27 CONFIDENTIAL  8.1.6.  Randomization and Dispensing Study Medication  
Randomization and study med ication kit assignment will be accomplished using an Interactive 
Randomization Tool (IRT) feature in the EDC system after all screening procedures have been 
completed and the subject has been determined to be eligible for the study. Site staff will witness  
the subject take the first dose of study medication in the clinic  as soon as possible following 
randomization  and record the date and time of medication intake in the EDC system.  
8.1.7.  Subject Instructions  
At each subject contact, site staff will instruct the subject regarding:  
1. Administration of study medication.  Subjects will be instructed to take the study medication 
(two tablets) twice daily with the morning and evening meals, approximately every 12 
hours (< 1 hour after food intake, preferably a high -fat meal but at a minimum a cereal bar) 
and a B complex vita min (Super B -Complex™, Igennus Healthcare Nutrition, Cambridge, 
UK).   
2. Completion of subject diary.   Subjects will be reminded to complete the  electronic diary 
and any questions will be answered.  
3. Use of birth control.   Female subjects of childbearing poten tial, if sexually active, will be 
instructed to continue an acceptable method of birth control for the duration of the study 
and for 1 month post -treatment.  Acceptable methods of birth control include a double 
barrier method, oral birth control pills, an IUD, or medroxyprogesterone acetate 
administered intramuscularly.  
4. Follow -up visits . Subjects will be reminded of the study schedule and of the next scheduled 
visit.  
5. Seeking emergency care or contacting the study physician or nurse . Subjects must be 
informed to seek emergency medical care or contact the study physician or nurse if they 
develop any of the following symptoms listed below at any point during the study.  
CONTACT STUDY PHYSICIAN  IF YOU HAVE :  
• Trouble breathing including sh ortness of breath  
• Severe headache, stiff neck, confusion or excessive somnolence  
• If fever (≥99°F or ≥37.2°C) returns after being absent for 24 hours  
• Increased difficulty breathing  
• Wheezing develops  
• New pain develops or pain localizes to one area, such as a n ear, the throat, the chest, 
or the sinuses  
• Symptoms become more severe or frequent  
• Symptoms recur or any difficulty breathing following 5 -10 days resolution of illness  
• An allergic -like reaction occurs or is suspected  
• Abnormal behavior  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 28 CONFIDENTIAL  8.1.8.  Day 2 -7 Subject Contact 
Site staff will contact each subject by telephone on study Days 2 -7 to verify:  
1. Did the subject take all expected doses of study medication?  
2. Did the subject complete all expected electronic diaries?  
3. Does the subject have worsening symptoms or adverse e vents that warrant an 
unscheduled visit?  
4. Does the subject have shortness of breath at rest? If yes , instruct the subject to come to 
the clinic for an unscheduled visit to screen for progression of  illness or refer to hospital 
as warranted . If the subject i s referred to the hospital or emergency department, the 
Investigator will attempt to obtain hospital records indicating SpO 2 or PaO 2/FiO 2 from 
the subject for the purposes of defining progression to severe COVID -19 illness. The 
SpO 2 or PaO 2/FiO 2 obtained f rom hospital records will be entered on an Unscheduled 
Visit eCRF.  
If the subject has missed medication or electronic diaries, the site staff will re -train the subject on 
the importance of medication and diary compliance.  
This contact may occur at the Day 4 or unscheduled visit in lieu of telephone contact.  
8.1.9.  Day 28 Subject Contact  
Site staff will contact each subject by telephone on study Day 28 to determine if the subject has 
experienced any new adverse events , developed severe COVID -19 illness,  or required  
hospitalization for any reason . 
If warranted, t he Day 28 subject contact may also occur in -person at the clinic or another 
location as agreed upon by the site and subject.  
8.2. Laboratory Assessments  
8.2.1.  Assessments in the Clinic  
A urine pregnancy test will be per formed in the clinic only for women of childbearing potential  
(post -menarche, pre -menopause, not surgically sterile)  at the Screening visit.  
8.2.2.  Central Laboratory Assessments  
A central laboratory will be used for safety, diagnostic virology, and serology testing.  A laboratory 
manual will be provided to each clinical site with sample collection and handling details.   
8.2.2.1.  Laboratory Safety Assessments  
Blood tests  for safety monitoring  will include hemoglobin, hematocrit, complete blood count (total 
and different ial), platelet count, random blood sugar, total cholesterol, HDL, LDL, triglycerides, 
albumin, AST, ALT, GGT, alkaline phosphatase, bilirubin (total/direct), BUN, creatinine , sodium, 
potassium, chloride.  
Routine urinalysis will include appearance, glucose , protein, and blood.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 29 CONFIDENTIAL  8.2.2.2.  Diagnostic Virology Testing  
Diagnostic virology testing will be performed using nasopharyngeal swab samples c ollected at the 
Baseline, Day 4 and  Day 10 . The nasopharyngeal sample for virology testing will be collected 
using a single n asopharyngeal swab inserted into both nostrils in accordance with procedures 
detailed in the study -specific laboratory manual.  
The ePlex® Respiratory Pathogen Panel (“ePlex RPP”, GenMark, Carlsbad, CA) will be used to 
detect  influenza A (non -specific as t o subtype); influenza A H1, H1N1 (2009), H3 subtypes; 
influenza B; RSV A and B; parainfluenza 1, 2, 3 and 4; hMPV; adenovirus; human EV/RV; 
coronavirus NL63, HKU1, 229E and OC43; Chlamydophila pneumoniae; and Mycoplasma 
pneumoniae.  
The Aptima® SARS -CoV -2 Assay (Hologic, Inc, San Diego, CA) will be used to detect SARS -
CoV -2. 
All Baseline nasopharyngeal swabs will be tested by the ePlex RPP and Aptima® SARS -CoV -2 
assays.  If the Baseline nasopharyngeal swab is positive for SARS -CoV -2, the Day 4 and 10 
nasopharyngeal swabs will be tested for SARS -CoV -2. If the Baseline nasopharyngeal swab is 
positive for EV/RV, the Day 4 and 10 nasopharyngeal swabs will be tested using the ePlex RPP.  
8.2.2.3.  Quantitative Virology Testing  
Nasopharyngeal swab samples testing positive for SARS -CoV -2 will be subjected to quantitative 
RT-PCR  for analysis of quantitative changes in viral RNA . 
8.2.2.4.  Serology Testing  
Baseline and Day 2 2 blood samples wi ll be tested for quantitative anti-SARS -CoV -2 antibodies.  
8.2.3.  Pharmacokinetics Assessments  
Blood samples for pharmacokinetics analysis will be sent to the central laboratory by the site and 
shipped to a referral laboratory for analysis. Sample collection and handling details will be 
included in the central laboratory manual.  
8.2.4.  Plan for Monitoring Viral Resistance  
If any Day 10 nasopharyngeal swab sample is positive for SARS -CoV -2 by the SARS -CoV -2 
assay  or for EV/RV by the ePlex RPP , the Baseline and Day 10 naso pharyngeal swab samples for 
the subject will be tested for post-treatment reduced susceptibility to tizoxanide.  
8.3. Subject Diary  
The subject diary will be used to generate primary efficacy data. Therefore, diary compliance is of 
critical importance.  
8.3.1.  Subject D iary Completion  
Subjects will complete a diary including : 
 Oral temperature taken using the study thermometer twice daily (morning and evening), 
and 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 30 CONFIDENTIAL   The FLU -PRO© symptoms questionnaire daily in the evening.  
The diary will be completed using the subject’s smartphone or provisioned device .  
Site staff will ensure subject access and ability to complete the diary  during the Baseline visit . 
Subjects will complete the first post -Screening diary at home on the evening of study Day 1.  
Subjects will receive electro nic reminders to complete the diary daily to ensure compliance.  
8.3.2.  Subject Diary Compliance Monitoring  
It is the responsibility of the clinical site to ensure that subjects are completing the diary as directed. 
E-mail notifications will be sent to the site da ily with a list of subjects who missed the previous 
day’s diary in order to direct follow -up contact with the subject to re -train on the importance of 
the diary. Site staff may also view a diary completion report at any time within the EDC system.  
8.4. Adverse Events and Serious Adverse Events  
8.4.1.  Definitio ns 
The following definitions will apply to the reporting of adverse events:  
1. Adverse Event:  Any unwanted physical, psychological or behavioral change experienced 
by a subject during the course of the study and a fter taking the first dose of study 
medication regardless of its severity or relation to the study.  Adverse events may include 
symptoms, signs, unexpected worsening of pre -existing conditions, clinically significant 
changes in laboratory values, diseases and syndromes, and significant and unexpected 
failures of pharmacological action of other medications.  Symptoms of viral respiratory 
infections (VRIs) (cough, sore, throat, nasal obstruction, fatigue, headache, myalgia, or 
feverishness) will not be report ed as adverse events.  
2. Serious Adverse Event:  Any adverse experience occurring at any dose that is fatal or life 
threatening; requires in -patient hospitalization or prolongation of an existing 
hospitalization; is a persistent significant disability/incap acity; is a congenital anomaly or 
birth defect; or is an important medical event that may not result in death, be life -
threatening, or require hospitalization but, based upon appropriate medical judgment, may 
jeopardize the subject and may require medical or surgical intervention to prevent one of 
the outcomes listed above.  
3. Unexpected Adverse Event:  Any adverse experience that is not identified in nature, 
severity, or frequency in the Investigator's Brochure for NTZ.  
4. Severity of adverse events  will be  assessed as mild, moderate, severe or potentially life -
threatening by the Investigator using the Toxicity Grading Scale Tables provided in 
Appendix 4 (derived and adapted from “Guidance for Industry: Toxicity Grading Scale for 
Healthy Adult and Adolescent  Volunteers Enrolled in Preventive Vaccine Clinical Trials”, 
US Dept. of HHS, FDA, CDER, September 2007 and the National Institutes of Health, 
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0).  
5. Causality (rela tionship to treatment)  will be assessed as follows:  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 31 CONFIDENTIAL  • Definitely Related : The adverse event is clearly related to the investigational agent(s) 
or research intervention: the adverse event has a temporal relationship to the 
administration of the investigational agent(s) or research intervention, follows a 
known pattern of response, and no alternative cause is present.  
• Probably Related : The adverse event is likely related to the investigational agent(s) or 
intervention: the adverse event has a temp oral relationship to the administration of the 
investigational agent(s) or research intervention, follows a known or suspected pattern 
of response, but an alternative cause may be present.  
• Possibly Related : There is a reasonable possibility that the event may have been 
caused by or is linked in a significant way to the research; the adverse event has a 
temporal relationship to the administration of the investigational agent(s) or research 
intervention, follows a suspected pattern of response, but an alterna tive cause is 
present.  
• Unrelated (or Not Related) : The adverse event is clearly NOT related to the 
investigational agent(s) or intervention: the adverse event has no temporal relationship 
to the administration of the investigational agent(s) or research in tervention, follows 
no known or suspected pattern of response, and an alternative cause is present.  
Under double -blind treatment conditions, it should be assumed that all subjects are taking 
the test drug.  
8.4.2.  Recording and Follow Up of Adverse Events  
At the t ime of each visit, the subject will be questioned regarding the occurrence and nature of any 
adverse events and all events will be recorded in the subject’s medical records and in the EDC 
system. Any subject affected will be examined by the Investigator as  deemed necessary to ascertain 
the course of the event and any residual effects. All adverse events must be followed until their 
resolution or stabilization even beyond the planned study period.  
All moderate and severe adverse events will be reviewed by th e Principal Investigator who will 
determine using his/her best clinical judgment whether they warrant the subject to be discontinued 
from the study.  The Sponsor will be notified immediately if a subject is discontinued from the 
study.  For all adverse eve nts that require the subject to be discontinued from the study, relevant 
clinical assessments and laboratory tests will be repeated as clinically indicated until final 
resolution or stabilization of the event(s).  
All subjects will be instructed to contact the Investigator, Investigator's assistants, or clinical 
personnel should the subject have any serious adverse experiences.   
An overdose is defined as any intentional or unintentional consumption of the drug by any route 
that exceeds the highest dose stat ed in the Investigator's Brochure  or in an investigational protocol, 
whichever dose is larger.  Overdoses without an associated adverse event should be recorded, but 
not reported as an adverse event.  
8.4.3.  Reporting Requirement  
The Principal Investigator is requ ired to notify The Romark Institute for Medical Research 
(Sponsor) immediately (within 24 hours of the initial report) of any unexpected, fatal, or life -
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 34 CONFIDENTIAL  9.3. Response Definitions  
Sustained Response:  A decrease in total FLU -PRO score from the 
previous diary with patient assessment that 
symptoms are at least “somewhat better than 
yesterday” , no oral temperature ≥100.4°F in the 
prior 24 hours, and no future increase in any  of the 
FLU -PRO domains except within  the following 
levels:  
FLU -PRO Domain* Background Level  
Body/Systemic  0.56 
Throat  0.67 
Eyes  0.67 
Gastrointestinal  2.00 
Head  2.00 
Nose  Score at time of response or 
0.75, whichever is greater  
Chest  Score at time of response or 
0.00, whichever is greater  
Cough  Score  at time of response or 
1.75, whichever is greater  
 * A diagram of the FLU -PRO domain/subdomain 
structure is attached as Appendix 5 . 
Time of Sustained Response:  The time of the first diary at which all  Sustained 
Response criteria are met.  
Time to Sustained Response:  The time (hours) from  the first dose of study 
medication and the Time of Sustained Response.  
Severe COVID -19 Illness:  Subject must have (1)  shortness of breath at rest 
and (2) SpO 2≤93% on room air or PaO 2/FiO 2 <300 . 
9.4. Statistical Methodology  
The statistical methodology is described briefly below and will be described in detail in the 
Statistical Analysis Plan.  
9.4.1.  Efficacy Analyses  
Efficacy analyses will be based on a population consisting of all subjects randomized who receive 
at least one dose of study medication and are positive for SARS -CoV -2 by Aptima® SARS -CoV -
2 Assay  at Baseline.  For time -to-event analyses, a test of signif icance (as described in the 
following) will be performed with descriptive statistics provided, including the use of Kaplan -
Meier figures.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 35 CONFIDENTIAL  There will be one primary efficacy analysis:  
• Time to Sustained Response for the NTZ treatment group will be compared t o that of the 
placebo treatment group using a stratified Gehan -Wilcoxon test (α=0 .05) where 
stratification will follow that used for randomization. Subjects without a Sustained 
Response recorded will be treated as censored as of the last diary without a do cumented 
Sustained Response , except for subjects who are hospitalized or die during the study, who 
will be censored at Day 21 (hour 504).  
Sensitivity analyses for the primary efficacy analysis will be described in the Statistical Analysis 
Plan.  
If the prim ary analysis is significant at the 0.05 level, the key secondary efficacy analys is will be 
formally evaluated at the 0.05 level as follows:  
• Proportions of subjects progressing to Severe COVID -19 Illness will be compared between 
the treatment groups using a  Cochran -Mantel -Haenszel (CMH) test stratified by the 
randomization strata.  
Exploratory analyses will be performed as follows:  
• Proportions of subjects positive for SARS -CoV -2 by  Aptima® SARS -CoV -2 Assay  at 
study Day 4 and Day 10  will be compared between the treatment groups using a Cochran -
Mantel -Haenszel (CMH) test stratified by the randomization strata.  
• Mean changes from baseline in quantitative SARS -CoV -2 RNA measured by RT -PCR  at 
Day 4 and Day 10 will be compared using a t-test. 
• Proportions of subjects hospitalized due to COVID -19 or complications thereof will be 
compared across the treatment groups using a CMH test stratified by the randomization 
strata.  
• Proportions of subjects with mortality related to COVID -19 or comp lications thereof will 
be compared across the treatment groups using a CMH test stratified by the randomization 
strata . 
9.4.2.  Population Pharmacokinetics Analysis  
On Day 4, plasma samples will be collected before the morning dose (at the trough) for 
determinatio n of drug concentration.  These data will allow for analysis of relationships between 
trough plasma concentrations and clinical and virologic response.   
Trough plasma concentrations of tizoxanide and tizoxanide glucuronide will be summarized 
descriptively  for NTZ -treated subjects  except those positive for EV/RV at Baseline .  Exploratory 
analyses will be conducted to evaluate the relationships between plasma concentrations and age, 
race, gender, body weight, body mass index, VRI and adverse events.  
Pharmaco kinetics data for subjects positive for EV/RV at Baseline will be analyzed as part of 
concurrently enrolling study RM08 -3009.  
9.4.3.  Safety Analyses  
All randomized subjects who receive at least one dose of study medication  except those positive 
for EV/RV at Basel ine will be evaluated for drug safety. Safety analyses will be done descriptively.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 36 CONFIDENTIAL  Safety  data for subjects positive for EV/RV at Baseline will be analyzed as part of concurrently 
enrolling study RM08 -3009.  
10. OPERATIONAL CONSIDER ATIONS  
10.1. Regulatory, Ethical and Study Oversight Considerations  
10.1.1.  Ethics  
The clinical trial will be performed in accordance with the guidelines set by the World Medical 
Assembly (Declaration of Helsinki, last amendment in Fortaleza, Brazil, October 2013).   
Informed consent will be obtained from each subject as described in Section 8.1.1. 
Prior written approval of the study protocol and of the informed consent form will be obtained  by 
the Sponsor  from the appropriate central or local IRB.   
Prior to study init iation, the Investigator will provide the IRB with required documents for review 
and approval. See Appendix 3: List of Essential Documents  for designation of documents that may 
be required by the IRB prior to study initiation or during the course of study conduct.  No site will 
screen subjects until the IRB has given full approval of required documents and the data approval 
letter identifying the IRB and the documents approved is delivered to the study Sponsor.  
For all protocol amendments (excluding the ones  that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable informed consent 
form and assent form revisions must be submitted promptly to the IRB for review and approval 
before implementation of the change(s), except when necessary to eliminate immediate hazard to 
the study subjects.  If a deviation from, or a change to the protocol was implemented to eliminate 
an immediate hazard to study subjects, then the implemented deviation or change, the re asons for 
it, and, if appropriate, the protocol amendment should be submitted to the IRB as soon as possible.  
The re -approval of the clinical study by the IRB should be documented in writing.  
At the end of the study, the Investigator (or Sponsor where requ ired) will notify the IRB about the 
study completion.  
10.1.2.  Investigator Responsibilities  
The Investigator is responsible for ensuring that the clinical study is performed in accordance with 
the protocol, current International Conference on Harmonization (ICH) g uidelines on Good 
Clinical Practice (GCP), and applicable regulatory and country specific requirements.  
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that invo lve the participation of human subjects.  
Compliance with this standard provides public assurance that the rights, safety, and wellbeing of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and tha t the clinical study data are credible.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 37 CONFIDENTIAL  10.1.3.  Quality Assurance and Quality Control  
The accuracy and reliability of the study data will be assured by the selection of qualified 
Investigators and appropriate study centers, review of protocol procedures with the I nvestigator 
and associated personnel prior to the study, and by periodic monitoring visits by the Sponsor or 
Sponsor’s representatives  (see Section 10.1.6 ). Written instructions will be provided for collection, 
preparation and shipment of biological sample s. 
The Sponsor will be entitled to inspect and audit the facilities used in the clinical and laboratory 
parts of the study, as well as to make anonymized copies of all the data files pertaining to the study. 
Similar procedures may also be conducted by agen ts of any regulatory body, either as part of a 
national GCP compliance program or to review the results of this study in support of a regulatory 
submission. The Investigator should immediately notify the Sponsor if they have been contacted 
by a regulatory agency concerning an upcoming inspection.  
Quality oversight of study management will be accomplished according to the study -specific 
Integrated Quality and Risk Management Plan.  
10.1.4.  Safety Oversight  
The Sponsor and Medical Monitor will be responsible for safet y oversight of the study. Procedures 
for safety oversight are described in the study -specific Medical Monitoring Plan.  
An Independent Data Monitoring Committee (IDMC) will be organized to monitor safety and 
futility for this study.  A full description of the IDMC procedures for this study will be detailed in 
the Medical Monitoring (Safety) Plan and IDMC Charter.   
10.1.5.  Data Han dling and Record Keeping  
10.1.5.1.  Data Collection and Management Responsibilities  
Sponsor Data management will be responsible for oversight of data collection,  cleaning and 
locking according to the study -specific Data Management Plan.  
Data will be collected on sit e-specific source data forms and transcribed  into a n electronic data 
capture (EDC) system  by site staff. The responsible study monitor(s) will verify data according to 
the Clinical Monitoring Plan, either remotely or at the clinical study site. The Investi gator will 
ensure that the data recorded are accurate and complete.  
Queries emerging during data cleaning will be generated within the EDC system by monitors or 
data management personnel. The Investigator and/or designee will answer the queries and update 
the source data, as needed.  
10.1.5.2.  Study Records Retention   
The Investigator/institution will maintain all CRFs, EDC source forms, and source documents that 
support the data collected from each subject, as well as all study documents as specified in 
ICH/GCP Secti on 8, and all study documents as specified by the applicable regulatory 
requirements for the duration required by applicable regulatory authorities or until the Sponsor 
informs the Investigator/institution that these documents are no longer needed.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 38 CONFIDENTIAL  If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.  
The Sponsor will be responsible  for maintaining the Trial Master File which i s a clear 
documentation of the course of the study.  
10.1.6.  Clinical Monitoring  
Clinical monitoring will be conducted by the Sponsor and/or a contract research organization 
(CRO) according to the study -specific Clinical Monitoring Plan.  
The Investigator will grant  representatives of the Sponsor's clinical operations team and quality 
team, as well as regulatory agencies and ethical committees access to inspect facilities and records 
(including subject charts) relevant to this study and agrees to assist the monitors in their activities, 
if requested.  
10.1.7.  Protocol Deviations   
Protocol deviations will be documented by the Investigator, reported to the institutional review 
board (IRB) as appropriate, and also reviewed by the assigned clinical research associate.  
Deviations will be reported in the clinical trial management system or applicable EDC.  Each 
deviation will be classified as major or minor according to the following definitions:  
Major protocol deviation:  A deviation that has an impact on subject safety, may substan tially 
alter risks to subjects, may have an effect on the integrity of the 
study data, or may affect the subject’s willingness to participate in 
the study  
Minor protocol deviation:  All other protocol deviations.  
10.1.8.  Study Discontinuation and Closure  
The study  may be discontinued under the following circumstances:  
1. The Sponsor reserves the right to discontinue the study at any time.  
2. Adverse event listings will be produced for safety monitoring at least once every two weeks 
during recruitment.  The data wi ll be tested to determine if there are greater than 20% of 
the subjects who have had ≥ Grade 3 adverse events considered by the Investigator to be 
possibly, probably or definitely related to the study drug (defined by the Toxicity Grading 
Scale Tables prov ided in Appendix 4). 
If greater than 20% of the subjects have at least one Grade 3 or Grade 4 adverse event 
considered to be possibly, probably or definitely related to the study drug by the study 
Medical Monitor, then the study must be stopped and the Ins titutional Review Boards, and 
FDA’s Division of Anti -Infectives will be notified.  All safety and efficacy data will be 
submitted to the FDA in a timely manner.  
10.1.9.  Data and Report Requirements  
See Appendix 3: List of Essential Documents  for designation of doc uments required from the 
Investigator by the Sponsor prior to approval and initiation of the study and before the study can 
be considered complete and terminated.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 39 CONFIDENTIAL  10.1.10.  Confidentiality and Privacy  
The collection and processing of personal data from subjects enrolled in this study will be limited 
to those data that are necessary to investigate the safety, quality, and utility of the investigational 
study drug(s) used in this study.  
These data will be collected and processed with adequate precautions to ensure confidentiality and 
compliance with applicable data privacy protection laws and regulations. Appropriate technical 
and organizational measures to protect the personal data against unauthorized disclosures or 
access, accidental or unlawful destruction, or a ccidental loss or alteration will be put in place.  
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity 
of study subjects confidential.  
The informed consent obtained from the subject includes explicit consent  for the processing of 
personal data and for the Investigator to allow direct access to his or her original medical records 
for study -related monitoring, audit, IRB review, and regulatory inspection.  This consent also 
addresses the transfer of the data to  other entities and to other countries.  All reports and 
communications relating to the study subjects will identify subjects only by initials and subject 
identification number.  
Data generated for the study will be stored by the Investigator in a limited -access file area and be 
accessible only to representatives of the study site, Romark, the IRB, and FDA/relevant regulatory 
agencies.  Medical information resulting from a subject’s participation in this study may be given 
to the subject’s personal physician or to the appropriate medical personnel responsible for the 
subject’s welfare.   
10.1.11.  Publication and Data Sharing  
Presentation and/or publication of the results of the study is encouraged provided that The Romark 
Institute for Medical Research is notified in a dvance of the author's intent and is given the 
opportunity to review the manuscript or abstract 45 days prior to its submission for presentation at 
a scientific meeting or for publication in a scientific journal.  The Investigators will have complete 
auton omy regarding the content and wording of any abstracts, presentations, and scientific 
publications arising from this study, including the decision of whether or not to publish.  
10.1.12.  Key Roles and Study Governance   
See Appendix 2 for a list of key personnel and contact information.   
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 40 CONFIDENTIAL  11. REFERENCES  
ALINIA (nitazoxanide) prescribing information. Romark, L.C., Tampa, FL, June 2019.  
Anderson VR, Curran MP. NTZ: A review of its use in the treatment of gastrointestinal 
infections. Drugs  2007;67:1947 -67. 
Ashton LV, Callan  RL, Rao S, Landolt GA. In vitro susceptibility of canine influenza A (H3N8) 
virus to nitazoxanide and tizoxanide. Vet Med Int  2010; 2010:891010.  
Backman JT, Filppula AM, Niemi M , Neuvonen PJ. Role of cytochrome P450 2C8 in drug 
metabolism and interactions . Pharmacol Rev  2016; 68:168 -241. 
Braakman I, Helenius J, Helenius A. Role of ATP and disulphide bonds during protein folding 
in the endoplasmic reticulum. Nature  1992; 356:260 -62. 
Braakman I, Hoover -Litty H, Wagner KR, Helenius A. Folding of influenza h emagglutinin in 
the endoplasmic reticulum J Cell Biol  1991; 114:401 -11. 
Cao J, Forrest JC, Zhang X. A screen of the NIH collection small molecule library identifies 
potential coronavirus. Antiviral Res  2015; 114:1 -10. 
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID -19): 
COVIDView – Key Updates for Week 22, ending May 30, 2020.  
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID -19): Symptoms 
of Coronavirus. Accessed 12 Jun 2020. Available at: https://www.cdc.gov/coronavirus/2019 -
ncov/symptoms -testing/symptoms.html  
Chang CW, Li HC, Hsu CF, Chang CY, Lo SY. Increased ATP gene ration in the host cell is 
required for efficient vaccinia virus production. J Biomed Sci  2009; 16:80.  
Chen L , Li Q, Zheng D, Jiang H, Wei Y, Zou L, Feng L, Xiong G, Sun G, Wang H, Zhao Y , 
Qiao J. Clinical Characteristics of Pregnant Women with COVID -19 in Wuhan, China. NEJM 
2020; 382:e100.  
Doms RW, Keller DS, Helenius A, Balch WE. Role of adenosine triphosphate in regulating the 
assembly and transport of vesicular stomatitis virus G pro tein trimers. J Cell Biol  1987; 
105:1957 -69. 
Goldberg B. New York survey suggests nearly 14% in state may have coronavirus antibodies. 
Reuters. 23 Apr 2020. Available at: https://www.reuters.com/article/us -health -coronavirus -usa-
new-york/new -york-survey -suggests -nearly -14-in-state-may-have -coronavirus -antibodies -
idUSKCN2252WN?il=0  
Goldman JD et al. Remdesivir for 5 or 10 Day s in Patients with Severe COVID -19. NEJM  
2020. Published online 27 May 2020. Available at: 
https://www.nejm.org/doi/full/10.1056/NEJ Moa2015301  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 41 CONFIDENTIAL  Hadad GM, Abdel Salam RA, Emara S. Validated and optimized high -performance liquid 
chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in 
human urine, plasma and breast milk. J Chromatogr Sci. 2012;50:509 -15. 
Hong SK, Kim HJ, Song CS, Choi IS, Lee JB, Park SY. Nitazoxanide suppresses IL -6 
production in LPS -stimulated mouse macrophages and TG -injected mice. Int Immunopharmacol  
2012; 13:23 -27. 
Johns Hopkins University and Medicine COVID -19 map. Johns Hopkins Coronavirus Resource 
Center. Accessed: 12 Jun 2020. Available at: https://coronavirus.jhu.edu/map.html  
Lee JH, Zhang Y, Zhao Z, Ye X, Zhang X, Wang H, Ye J. Intracellelular ATP in balance of pro -
inflammatory and anti -inflammatory cytokines in adipose tiss ue with and without tissue 
expansion. Int J Obes  2017; 41:645 -51. 
Li, X , Ma, X. Acute respiratory failure in COVID -19: is it “typical” ARDS?. Crit Care 24, 198 
(2020). https://doi.org/10.1186/s13054 -020-02911 -9 
Mirazimi A, Svensson L. ATP is required for  correct folding and disulfide bond formation 
rotavirus VP7. J Virol  2000; 74:8048 -52. 
OECD. OECD Economic Outlook, June 2020 – The world economy on a tightrope. Accessed 12 
Jun 2020. Availab le at: http://www.oecd.org/economic -outlook/june -2020/  
Piacentini S, La Frazia S, Riccio A, Pedersen JZ, Topai A, et al. Nitazoxanide inhibits 
paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein -specific 
thiol oxidoredu ctase ERp57. Sci Rep 2018; 8:10425.  
Powers JH, Bacci ED, Leidy NK, Poon JL, Stringer S, et al. Performance of the inFLUenza 
patient -reported outcome (FLU -PRO) diary in patients with influenza -like illness (ILI). PLoS 
ONE  2018 13(3):d0194180.  
Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti -
influenza molecules targeting viral hemagglutinin at the post -translational level. J Biol Chem 
2009; 284:29798 -808. 
Rossignol JF, van Baalen C. Broad -spectrum ant iviral nitazoxanide inhibits ATP -dependent 
replication of respiratory viruses and proinflammatory cytokines [Abstract]. Presented at the 2nd 
International Meeting on Respiratory Pathogens. Singapore, March 7 -9, 2018.  
Rossignol JF. Nitazoxanide, a new drug  candidate for the treatment of Middle East respiratory 
syndrome coronavirus. J Infect Public Health  2016; 9:227 -30. 
Rossignol JF. Nitazoxanide: A first -in-class broad -spectrum antiviral agent. Antiviral Res  2014; 
110:94 -103. 
Sag D, Carling D, Stout RD, Suttles J. AMP -activated protein kinase promotes macrophage 
polarization to an anti -inflammatory functional phenotype. J Immunol  2008; 181:8633 -41. 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 42 CONFIDENTIAL  Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, et al. Antiviral susceptibility of variant 
influenza A(H3 N2)v viruses isolated in the United States from 2011 to 2013. Antimicrob Agents 
Chemother  2014; 58:2045 -51. 
Sood N, Simon P, Ebner P. Seroprevalence of SARS -CoV -2-Specific Antibodies Among Adults 
in Los Angeles County, California, on April 10 -11, 2020. JA MA 2020. Published online May 
18, 2020. Available at: https://jamanetwork.com/journals/jama/fullarticle/2766367  
St. Jude Children’s Research Hospital. Infections in Immunocompromised Patients.  Accessed 
22 Jun 2020.  Available at: https://www.stjude.org/treatment/patient -resources/caregiver -
resources/infection -tips/infections -immunocompromised -patients.html  
Tilmanis D, van Baalen C, Oh DY, Rossignol J -F, Hurt AC. The susceptibility of circulating 
human influenza viruses to tizoxani de, the active metabolite of nitazoxanide. Antivir Res  2017; 
147:142 -48. 
van der Vries E, Stittelaar KJ, van Amerongen G, et al. Prolon ged influenza virus shedding and 
emergence of antiviral resistance in immunocompromised patients and ferrets.  PLoS Patho g. 
2013;9(5):e1003343.  
Wang M, Cao R, Zhang L, Yang X, Liu J, et al. Remdesivir and chloroquine effectively inhibit 
the recently emerged novel coronavirus (2019 -nCoV) in vitro. Cell Res  2020; 30:269 -71. 
Wang W, Yang X, de Silanes IL, Carling D, Gorospe M. Increased AMP:ATP Ratio and AMP -
activated protein kinase activity during cellular senescence linked to reduced HuR function. J 
Biol Chem  2003; 278:27016 -23. 
Wölfel, R., Corman, V.M., Guggemos, W.  et al.  Virological assessment of hospitalized patients 
with COVID -2019.  Nature  581, 465–469 (2020).  
Yu J, Powers JH, Vallo D, Falloon J. Evaluation of efficacy endpoints for a phase IIb study of a 
respiratory syncytial virus vaccine in older adults using patient -reported outcomes with 
laboratory confirmation. Value Health  2020; 23:227 -35. 
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 
2019. NEJM  2020; 382:727 -733. 
 
 
 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 44  CONFIDENTIAL  Summary of Changes  
Change 5:  Page 25, Randomization and Dispensing Study Medication  
Updated “Site staff will witness the subject take the first dose of study medication in the clinic and record the date and time of 
medication intake in th e EDC system”  to “Site staff will witness the subject take the first dose of study medication in the clinic 
as soon as possible following randomization and record the date and time of medication intake in the EDC system.”  
Change 6:  Page 27, Day 2 -7 Contac t 
Updated “4. Does the subject have shortness of breath at rest? If yes , instruct the subject to come to the clinic for an 
unscheduled visit to screen for progression of illness including determination of PaO 2/FiO 2.” to “4. Does the subject have 
shortness of breath at rest?  If yes, instruct the subject to come to the clinic for an unscheduled visit to screen for progression 
of illness or refer to hospital as warranted. If the subject is referred to the hospital or emergency department, the Investi gator 
will attempt to obtain hospital records indicating SpO 2 or PaO 2/FiO 2 from the subject for the purposes of defining progression 
to severe COVID -19 illness. The SpO 2 or PaO 2/FiO 2 obtained from hospital records will be entered on an Unscheduled Visit 
eCRF.  
Chang e 7: Page 27, Diagnostic Virology Testing  
Added: “The nasopharyngeal sample for virology testing will be collected using a single nasopharyngeal swab inserted into 
both nostrils in accordance with procedures detailed in the study -specific laboratory manual.”  
Replaced “Panther Fusion”  with “ Aptima®” 
Replaced: “Post -baseline samples (Days 4 and 10) will only be tested by the SARS -CoV-2 assay and will only be tested if the 
sample from the preceding timepoint was positive for SARS -CoV-2. For example, a su bject who is positive for SARS -CoV-2 at 
Baseline will have the Day 4 sample tested by the SARS -CoV-2 assay. If the subjects’ Day 4 sample is negative for SARS -CoV-
2, the Day 10 sample will not be tested.”  
With: “If the Baseline nasopharyngeal swab is posit ive for SARS -CoV-2, the Day 4 and 10 nasopharyngeal swabs will be 
tested for SARS -CoV-2.” 
Change 8:  Page 30: Management of Subjects Requiring Hospitalization  
Added:  
8.4.4 Management of Subjects Requiring Hospitalization  
Subjects requiring hospitalization for any reason during the course of the study will receive local standard of care under the 
supervision of the hospital’s attending physicians. The Investigator will attempt to follow up on the subject to obtain compl ete 
data for a narrative of the Serious  Adverse Event and complete safety follow up procedures for the study as feasible.  
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 46  CONFIDENTIAL  Summary of Changes  
Change 2:  Page 8, Synopsis  
Updated the following to reflect Day 28 contact:  
“The safety of study drug administration will be monitored by assessment of adverse events from baseline through the Day 28 
study exit, clinical laboratory testing at baseline and on Day 10, physical examinations and vital signs assessments at 
screening, Day 10 and Day 22 and telep hone monitoring/at home visits during Day 2 through Day 7 and Day 28. ” 
Page 9, Schedule of Assessments   
Added subject contact at Day 28 (+3 days).  
Page 27, 8.1.9 Day 28 Subject Contact  
Added section with text: “ Site staff will contact each subject by telep hone on study Day 28 to determine if the subject has 
experienced any new adverse events, developed severe COVID -19 illness, or required hospitalization for any reason.  
If warranted, the Day 28 subject contact may also occur in -person at the clinic or anoth er location as agreed upon by the site 
and subject .” 
Change 3:  Page 9, Schedule of Assessments  
Corrected Day 22 visit window from “ ±3” to “ +3”. 
Change 4:  Page 16, 4.1 Study Design Overview  
Added: “ We expect that a large number of subjects enrolled will be positive for Enterovirus/Rhinovirus (EV/RV). Efficacy and 
safety data for subjects who are positive for EV/RV at Baseline will be analyzed as part of concurrently enrolling study RM08 -
3009. ” 
Page 28, 8.2.2.2 Diagnostic Virology Testing  
Added: “ If the Ba seline nasopharyngeal swab is positive for EV/RV, the Day 4 and 10 nasopharyngeal swabs will be tested using 
the ePlex RPP.”  
Page 28, 8.2.4 Plan for Monitoring Viral Resistance  
Added: “ or for EV/RV by the ePlex RPP ” 
Page 34, 9.4.2 Population Pharmacokineti cs Analysis  
Updated text, “ Trough plasma concentrations of tizoxanide and tizoxanide glucuronide will be summarized descriptively for 
NTZ-treated subjects ” to add “ except those positive for EV/RV at Baseline. ” 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 48  CONFIDENTIAL  Summary of Changes  
Change 4:  Page 3 5, 9.4.1 Efficacy Analyses  
Updated:  
• Proportions of subjects positive for SARS -CoV-2 by TCID 50 at study Day 4 and Day 10 will be compared between the 
treatment groups using a Cochran -Mantel -Haenszel (CMH) test stratified by the randomization strata.  
• Mean changes from baseline in SARS -CoV-2 TCID 50 at Day 4 and Day 10 will be compared using a t -test. 
To: 
• Proportions of subjects positive for SARS -CoV-2 by Aptima® SARS -CoV-2 Assay  at study Day 4 and Day 10 will be compared 
between the treatment groups using a Cochran -Mantel -Haenszel (CMH) test stratified by the randomization strata.  
• Mean changes from ba seline in quantitative SARS -CoV-2 RNA measured by RT -PCR at Day 4 and Day 10 will be compared 
using a t -test. 
Change 5:  Page 6, Synopsis  & Page 17, Study Overview  
Updated anticipated end of enrollment from December 2020 to January 2021  
Change 6:  Page 7, Synopsis  & Page 17, Choice of Duration of Follow Up  
Corrected study duration from 22 days to 28 days  
Change 7:  Page 49, Study Contact Information  
Updated Sponsor Project Management and Central Laboratory contact information  
 
 
 
Protocol RM08 -3008 FINAL v4.0  January 11, 2021  
 59  CONFIDENTIAL  APPENDIX  5. FLU -PRO DOMAIN/SUBDO MAIN STRUCTURE  
 
